null Christos Tsoukas, CM, MD, FRCP(C), FACP, FCAHS
Immune risk phenotype • inflammation • biomarkers • cardiovascular • immunopathology • cohort studies • T cell activation • primary immune deficiency.
My research focuses on the interplay of HIV-associated chronic inflammation, immune activation, and accelerated aging. The risk of having medical conditions that are more frequently found in the elderly, such as heart disease, stroke, osteoporosis and dementia may relate to the premature aging of the immune system. I am currently conducting two large clinical studies of healthy Canadians and those with HIV to define the biological age of individuals as opposed to numerical age. Understanding immune parameters related to biological age may provide insight on why coronary artery disease may occur earlier in those with chronic inflammatory diseases.
Srinivasa BT, Alizadehfar R, Desrosiers M, Shuster J, Tsoukas CM. "Adult Primary Immune Deficiency: what are we missing?" Am J Med, 125(8), 779-86, 2012.
Ndumbi P, Gillis J, Raboud J, Cooper C, Klein M, Loutfy MR, Machouf N, Burchell AN, Montaner JSG, Hogg RS, Tsoukas C, the Canadian Observational Cohort Collaboration (CANOC). "Clinical impact of altered T-cell homeostasis in treated HIV-infected patients enrolled in the Canadian Observational Cohort (CANOC)" (AIDS, E-pub August 6, 2013).
Ndumbi P, Gillis J, Raboud JM, Klein M, Cooper C, Hogg RS, Loutfy M, Machouf N, Montaner JSG, Rourke SB, Tsoukas C. "Characteristics and Determinants of Normalization of the T-cell Phenotype in HIV-1 Infected Individuals Receiving Long-Term Antiretroviral Therapy". (Accepted to HIV Medicine, September 2013).
Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JSG, Rourke SB, Tsoukas C, Klein MB, CANOC Collaboration. "Predictors of CD4:CD8 ratio normalization and its affect on health outcomes in the era of combination antiretroviral therapy", PLOS ONE, 8(10), 2013).
Tsoukas C, Gilbert L, Lewis T, Hatzakis G, Falcon R, Mrus J. Improvements in immune function and activation with 48-week darunavir/ritonavir-based therapy: GRACE (gender, race and clinical experience) immunology substudy, (Accepted ISRN AIDS, Nov 2013).